Every time through the AI newsletter, investors ask questions on the investor interactive platform: Mr. Qiu, Professor Yuan Guoyong of the University of Hong Kong recently revealed that the University of Hong Kong has developed a nasal spray new crown vaccine in Hong Kong for the first phase of clinical trials, and the vaccine for the second phase of testing has been made in the Mainland. In the process of customs clearance, I would like to ask the company whether the above-mentioned vaccine of Hong Kong University is produced by the company. Yuan also mentioned that Wantai nasal spray vaccine has started the third phase of clinical trials in the Philippines. Is the company true? thanks.
Wantai Bio(603392.SH) stated on the investor interactive platform on November 22 that the nasal spray new crown vaccine mentioned by Professor Yuan of the University of Hong Kong is not a company product, nor is it produced by the company; the company’s nasal spray new crown vaccine developed in cooperation with Xiamen University and Hong Kong University Recently, it obtained the Phase III clinical trial approval issued by the South African Drug Administration, marking that the nasal spray new crown vaccine has entered the international multi-center phase III clinical trial stage. In order to accelerate the clinical trials of the nasal spray new crown vaccine, the company plans to conduct clinical trials in 11 countries including South Africa, Indonesia, and the Philippines.
(Source: Daily Economic News)
Article source: Daily Economic News
Editor in charge: 91
Original title: Wantai Bio: The co-developed nasal spray new crown vaccine recently obtained the Phase III clinical trial approval issued by the South African Drug Administration
Solemnly declare: The purpose of this information released by Oriental Fortune.com is to spread more information and has nothing to do with this stand.
Scan the QR code to follow
Oriental Wealth Official Website WeChat